Yu ZJ, Xu QZ, Zhou LJ, Sui JL, Zhang SM, An J, Wang Y, Zhou PK. Over-expression of DNA-PKcs in hepatocarcinoma tissues and the antiproliferative effect mediated by down-regulating its expression with siRNA.
Shijie Huaren Xiaohua Zazhi 2007;
15:3815-3821. [DOI:
10.11569/wcjd.v15.i36.3815]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To characterize the difference in DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression between hepatocarcinoma tissues and non-tumor liver tissues, and to understand the biological significance of the altered expression of DNA-PKcs in cancer cells.
METHODS: DNA-PKcs expression was examined in 86 specimens of hepatocarcinoma and hepatic cholangiocarcinoma by immunohistochemistry analysis on tissue-arrays and ordinary pathological tissue slices. DNA-PKcs protein was detected in culture cells by Western blotting analysis. The siRNA was used to silence DNA-PKcs expression in HepG2 cells. Cell proliferation was evaluated by growth curve analysis, and radiosensitivity was tested using a colony-forming ability assay.
RESULTS: Tissue-array analysis showed that the proportions of cases with a DNA-PKcs expression level of < 25% (very low), 25%-50% (low), 51%-75% (medium) and > 75% (high) were 15%, 20%, 23.3% and 41.7%, respectively, among the 60 hepatocarcinoma tissue specimens. The proportions of the 64 normal liver tissues showing these DNA-PKcs expression levels were 68.7%, 10.9%, 12.6% and 7.8%, respectively. This result indicated that DNA-PKcs expression in cancer tissues was significantly higher than that in normal tissues (P = 0.0008). Immunohistochemistry analysis of ordinary pathological tissue slices also showed that DNA-PKcs levels in the hepatocarcinoma and hepatic cholangiocarcinoma tissues (total 26 specimens) were higher than those in the non-tumor liver tissues (P = 0.001). Moreover, the cultured human liver cancer cell lines HepG2, 7721 and 7402 also exhibited much higher levels of DNA-PKcs than normal liver LO2 cells. Silencing of DNA-PKcs mediated by siRNA resulted in not only an increased sensitivity of HepG2 cells to ionizing radiation, but also decreased proliferation HepG2 cells. We further demonstrated that the expression of c-Myc oncoprotein was also depressed following the down-regulation of DNA-PKcs.
CONCLUSION: DNA-PKcs is overexpressed in hepatocarcinoma tissues as well as cultured liver cancer cells. Targeting DNA-PKcs is an anticancer strategy acting through at least two mechanisms: directly decreasing the proliferation of cancer cells via, at least, depressing c-Myc oncoprotein; and sensitizing cancer cells to radiotherapy or chemotherapy with DNA-damaging agents.
Collapse